In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thermo Fisher Dionex

Division of Thermo Fisher Scientific Inc.
www.dionex.com

Latest From Thermo Fisher Dionex

Device/Diagnostics Quarterly Deal Statistics, Q3 2012

Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.

Medical Device Deals

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q4 2010

In the fourth quarter, medical device companies raised $1.1 billion, a third of which was represented by follow-on public offerings. Acquisitions were strong overall, holding steady with 15 transactions - the same as Q3 - but only slightly less in money paid, $6 billion. In vitro diagnostic/research companies, like medical device, also ended 2010 on a high note, with funding totaling $511 million in Q4. The majority of the money spent on IVD/research acquisitions came from Thermo Fisher Scientific's buy of Dionex for $2.1 billion.
Medical Device

Deals Shaping the Medical Industry (01/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Glycomics: Sugar Coating is More than Decoration

By the mid 1990s, most of the early carbohydrate drug development companies were either defunct or had repositioned themselves. But academia continued to advance gycobiology analysis tools. Today, thanks to improved mass spec and bioinformatic methods, as well as newly-revealed structure-activity relationships, a new generation of glycomics companies has a chance to succeed where forebears failed.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Dionex Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Thermo Fisher Scientific Inc.
  • Senior Management
  • Craig A McCollam, EVP & CFO
    Christopher A Pohl, SVP, R&D & CSO
  • Contact Info
  • Thermo Fisher Dionex
    Phone: (408) 737-0700
    1228 Titan Way
    P.O. Box 3603 Sunnyvale, CA 94085
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register